Envista Holdings Corp (NVST) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Low returns ⢠Heavy operating spend NVST combines strong liquidity and positive free cash flow with healthy gross margins, but suffers very low returns, high operating costs, large intangibles and a richly priced earnings multiple.
Price Behavior
Key Price Behavior Insights: ⢠Below last month ⢠Short-term downtrend ⢠High intraday volatility Support Level: $26.80â$27.90 Resistance Level: $29.00â$30.30 Price is trading below its last month average (~$28.70) at $26.86, in a short-term downtrend toward support around $26.80â$27.90 after failing to reclaim resistance near $29.00â$30.30; monitor for a break below support or a move above resistance for directional confirmation.
Sentiment & News
Key News Insights: ⢠Earnings beat ⢠Analyst upgrades ⢠Margin pressure Envista surged on stronger-than-expected Q4 results, analyst upgrades and estimate revisions that drove a 52-week high and heightened peer comparisons, though margin pressures temper the outlook.
AI Summary
NVST has shifted from a speculative recovery to a cashâflowâdriven operational turnaroundâevidenced by sizable positive FCF and Spark profitabilityâbut the stock only merits conviction if management delivers sustained EBITDAânetâincome conversion and concrete capitalâallocation actions (buybacks/debt paydown) rather than a oneâquarter earnings beat.
Description
Envista Holdings Corp., headquartered in Brea, California, manufactures and sells a broad range of dental products and tools and employs about 12,800 full-time staff. The company operates two reporting segments: Specialty Products & Technologies, which supplies dental implant and prosthetic systems, orthodontic products and related treatment software; and Equipment & Consumables, which provides dental office equipment, imaging and visualization systems, restorative and endodontic materials, and infection-prevention supplies. Its offerings support diagnosis, treatment and routine clinical procedures across general and specialty dental practices.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 10 | Feb 17 | NVST | Envista Holdings Corp | Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty. | Closed | -7.0% |